Half Year 2025 DiaSorin SpA Earnings Call Transcript
Key Points
- Diasorin SpA (DSRLF) reported a solid quarter with top-line growth and a margin of 36%, in line with expectations.
- The immuno diagnostics segment grew by 8% in Q2, driven by strong performance in North America and Europe.
- The company signed a significant million-dollar contract in the US, marking a strategic win in the healthcare system.
- Molecular diagnostics, excluding COVID, showed an 8% growth in Q2, with a strong performance in the multiplex syndromic business.
- The company is on track to meet its target of adding 75 new customers by the end of the year, with 40 active customers already secured.
- China remains a challenging market with a double-digit decrease in revenues due to the impact of VBP, although it represents less than 5% of total revenue.
- The company faces foreign exchange headwinds, impacting revenues by approximately €11 million in the quarter.
- Gross margin remained stable at 66%, but tariffs and the full operation of the Chinese manufacturing plant added pressure.
- The company anticipates higher operating expenses in the second half of the year due to salary cycles and discretionary costs.
- The discontinuation of the Aries platform resulted in a revenue loss of €5.5 million in H1 2024, with no sales in 2025.
Good afternoon. This is the Corso conference operator. Welcome and thank you for joining the DiaSorin H1 2025 results conference call. As a reminder, all participants are listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and 0 on their telephone. At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of Diasain. Please go ahead, sir.
Thank you.
Ladies and gentlemen, good afternoon and welcome to the H1.
First call as usual. I'm going to give some general comments on the business and then Mr. Petron, our CFO is going to take you through the numbers.
Was a solid quarter for the in terms of top line growth and margin quarter revenues ex COVID growth 7% in line with expectation making H125 plus 8%.
Quarter to a margin 36%.
35 so in line what we expect to achieve by Mr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
